Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the use of prophylactic bismuth subsalicylate
(BSS) has an effect on the acquisition of travelers' diarrhea (TD) or antimicrobial
resistance (AMR) genes in fecal samples among international travelers who departed from the
United States to South East Asia, South Central Asia, or Africa. Our hypotheses will be
tested using a double-blinded, placebo controlled randomized clinical trial with participants
from a pre-travel health clinic in the United States.
Phase:
Phase 3
Details
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborators:
New York Center for Travel and Tropical Medicine Procter and Gamble The New York Center for Travel and Tropical Medicine